Greenwich LifeSciences (Nasdaq: GLSI) is a public biopharmaceutical company located in Houston, TX that is developing GP2, a novel peptide immunotherapy, planning to commence a Phase III trial. In a completed Phase IIb study, no recurrences have been observed in the Her2/neu 3+ adjuvant setting after median 5 years follow-up, if the patient received the 6 primary intradermal injections over the first 6 months. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including 75% of breast cancers.